hashimoto's and semaglutide Comparative safety side effects of and tirzepatide: Implications for clinical decision-making in obesity management The Thyroid Twist: How GLP-1

Recent federal discussions around medication pricing could influence future brand-name costs, but compounded options already bypass these delays

Label each vial immediately after reconstitution with the date, concentration, and peptide name using waterproof labels

GLP-1 wars The biggest pharma trade of the decade is breaking in real time

The existing evidence base consists primarily of: Small observational studies in patients with diabetes who also have inflammatory conditions Mechanistic studies exploring theoretical anti-inflammatory pathways Indirect evidence from cardiovascular outcome trials showing reduced inflammatory markers in people with type 2 diabetes (which cannot be extrapolated to rheumatoid arthritis or to microdosing) NICE guidance for rheumatoid arthritis management (NG100) does not include GLP-1 receptor agonists among recommended treatment options